2022 - Research.com Best Female Scientist Award
Hope S. Rugo mainly investigates Internal medicine, Oncology, Breast cancer, Cancer and Metastatic breast cancer. Her work focuses on many connections between Internal medicine and other disciplines, such as Surgery, that overlap with her field of interest in Gastroenterology. Her research in Oncology intersects with topics in Trastuzumab, Chemotherapy, Phases of clinical research, Carboplatin and Hazard ratio.
Her Breast cancer research is multidisciplinary, relying on both Everolimus and Progression-free survival. Her research investigates the connection between Cancer and topics such as Physical therapy that intersect with issues in Psychological intervention. The Metastatic breast cancer study combines topics in areas such as Taxane, Capecitabine, Hormone receptor, Disease and Bevacizumab.
Hope S. Rugo mainly focuses on Internal medicine, Oncology, Breast cancer, Cancer and Metastatic breast cancer. Internal medicine connects with themes related to Surgery in her study. Hope S. Rugo has included themes like Taxane, Phases of clinical research, Hormone receptor, Letrozole and Clinical endpoint in her Oncology study.
She combines subjects such as Bevacizumab, Clinical trial, Adverse effect, Gynecology and Stage with her study of Breast cancer. She studied Metastatic breast cancer and Vinorelbine that intersect with Gemcitabine and Eribulin. Hope S. Rugo has researched Chemotherapy in several fields, including Gastroenterology and Randomized controlled trial.
Her primary areas of investigation include Internal medicine, Oncology, Breast cancer, Cancer and Metastatic breast cancer. The Chemotherapy, Triple-negative breast cancer, Hazard ratio and Adverse effect research Hope S. Rugo does as part of her general Internal medicine study is frequently linked to other disciplines of science, such as In patient, therefore creating a link between diverse domains of science. Her Oncology research also works with subjects such as
Neutropenia is closely connected to Gastroenterology in her research, which is encompassed under the umbrella topic of Breast cancer. Her studies in Cancer integrate themes in fields like Cancer research and Talazoparib. Her research integrates issues of Taxane, Regimen, Progressive disease and Capecitabine in her study of Metastatic breast cancer.
Her primary areas of study are Internal medicine, Oncology, Breast cancer, Cancer and Chemotherapy. Internal medicine is frequently linked to Placebo in her study. Her studies in Oncology integrate themes in fields like Pembrolizumab, Gemcitabine, Trastuzumab and Palbociclib.
She focuses mostly in the field of Breast cancer, narrowing it down to matters related to Gastroenterology and, in some cases, Clinical endpoint. Her work in the fields of Cancer, such as Fulvestrant and Aromatase inhibitor, intersects with other areas such as Cyclin-dependent kinase 4. Her Chemotherapy study incorporates themes from Talazoparib, Veliparib, Olaparib and PARP inhibitor.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
José Baselga;Mario Campone;Martine Piccart;Howard A. Burris.
The New England Journal of Medicine (2012)
Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer
Kathy D. Miller;Linnea I. Chap;Frankie A. Holmes;Melody A. Cobleigh.
Journal of Clinical Oncology (2005)
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn;Miguel Martin;Hope S. Rugo;Stephen Jones.
The New England Journal of Medicine (2016)
Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy
David G. DeNardo;David G. DeNardo;Donal J. Brennan;Elton Rexhepaj;Brian Ruffell.
Cancer Discovery (2011)
Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
Kimberly L. Blackwell;Harold J. Burstein;Anna Maria Storniolo;Hope Rugo.
Journal of Clinical Oncology (2010)
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
F. Cardoso;A. Costa;E. Senkus;M. Aapro.
Annals of Oncology (2017)
Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy
Howard A. Burris;Hope S. Rugo;Svetislava J. Vukelja;Charles L. Vogel.
Journal of Clinical Oncology (2011)
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
Jennifer K. Litton;Hope S. Rugo;Johannes Ettl;Sara A. Hurvitz.
The New England Journal of Medicine (2018)
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
Paul M Ridker;Jean G MacFadyen;Tom Thuren;Brendan M Everett.
The Lancet (2017)
Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer
José Baselga;Vladimir Semiglazov;Peter van Dam;Alexey Manikhas.
Journal of Clinical Oncology (2009)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: